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Understanding and controlling the in vitro release behavior of a formulation is a first step toward ratio-
nalized selection of a solubility enhancing formulation strategy with a desired release profile in vivo.
Therefore six model formulations, representing three different formulation strategies, were
physicochemically analyzed and their in vitro release was determined.
Solid dispersions based on a PLGA/PVP matrix were compared to solid dispersions in a pure PLGA
matrix. Additionally these solid dispersion strategies were compared to the strategy of particle size
reduction by means of an API microsuspension.
Depending on composition and manufacturing method, formulations varied in particle size, porosity,
phase behavior, surface coverage and physical state of the API. This resulted in observed differences in
their in vitro release profile.
For the various formulation strategies tested both a porous PLGA-based formulation and PLGA/PVP-
based formulations, resulted in vitro in sustained release of the poorly soluble API with over 50% of drug
released after 24 h. For PLGA-based formulations the porosity was identified as a critical parameter influ-
encing in vitro drug release. For the PLGA/PVP-based formulations the release rate can be tailored by the
amount of PLGA present. Particle size reduction resulted in immediate total drug release.
 2014 Elsevier B.V. All rights reserved.1. Introduction
Therapy compliance is crucial in limiting the development of
resistance of human immunodeficiency virus (HIV) toward anti-
HIV medication in both HIV treatment and pre-exposure prophy-
laxis (PrEP) [1–4]. Long-acting formulations are desirable as dosing
frequency will be significantly reduced which favors patient adher-
ence. Therefore we have developed intramuscularly injectable
spray-dried microspheres as a novel formulation platform for the
long-term prophylaxis of infection with HIV [5,6]. Currently formu-
lations based on the strategy of drug particle size reduction are
under evaluation as long-acting injectables for PrEP [7]. With the
suggested formulation strategy based on spray-dried polymeric
microspheres we aim to develop an additional formulationapproach for this type of drug delivery systems with the potential
to tailor drug release by varying characteristics of the polymers
used. Moreover, this approach might be relevant for drugs for
which no stable micro- or nanosuspensions can be obtained.
Our formulation strategy was based on the solid dispersion of a
poorly soluble HIV protease inhibitor (PI) as the active pharmaceu-
tical ingredient (API) in a polymeric matrix consisting of water-
soluble polyvinylpyrrolidone (PVP) and water-insoluble poly
(lactic-co-glycolic acid) (PLGA). This combination of materials
aimed to secure both solubility enhancement by molecular disper-
sion of the drug (in PVP) and long-term release (by PLGA). The
PLGA/PVP microspheres were produced via spray drying as this
technique allows simultaneous processing of both water-soluble
PVP and water-insoluble PLGA. Additional benefits of spray drying
as a production technique are its scalability and industrial
applicability.
Solid dispersions are an intensively investigated formulation
strategy for solubility enhancement of poorly soluble drugs
[8–12]. However, there are multiple approaches to enhance the
dissolution rate and/or solubility such as particle size reduction,
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and lipid based systems [13]. At present no scientific rationale
exists for selecting a particular enabling strategy, however, the
selection is crucial as it will influence the in vivo performance of
the resulting formulation. The present study provides an insight
into this complicated decision making process by evaluating how
structural and physicochemical characteristics influence in vitro
release behavior of PLGA-based injectable formulations. Identifica-
tion and adequate manipulation of critical structural and physico-
chemical formulation attributes to the in vitro release might be
used to develop a formulation with desired release characteristics
in vivo, i.e. an adequate drug release for several weeks, in a further
stage of the development.
In the present study the in vitro behavior of the formulation
strategy of a solid dispersion in a binary polymeric matrix combin-
ing a water-insoluble polymer (PLGA) with a water-soluble poly-
mer (PVP) (strategy 1) was evaluated. The in vitro performance of
this formulation strategy was compared to the in vitro performance
of two other strategies. The second strategy involved formulating
the poorly soluble API as a solid dispersion in a polymeric matrix
made up of pure PLGA. PLGA is already well established as a formu-
lation matrix for long-term release as exemplified by commercial
products such as Trelstar Depot (Debio RP) [14] and
RisperdalConsta (Janssen) [15]. Hence, the current formulations
differed at the level of the polymeric matrix and can be divided
into two groups, namely formulations based upon a PLGA/PVP
matrix (strategy 1) and those made up of a pure PLGA matrix
(strategy 2). Consequently the potential benefit of the inclusion
of PVP was assessed.
Additionally, these solid dispersion systems were compared to
the strategy of particle size reduction by means of an API microsus-
pension (strategy 3). Particle size reduction is a thoroughly studied
strategy to increase dissolution rate of poorly soluble compounds.
This is exemplified by various publications on micro- and nanopar-
ticles aiming to improve the dissolution performance of a poorly
soluble compound [13,16,17]. This approach has already resulted
in the production of successfully marketed formulations such as
Invega Sustenna (Janssen) [18] and Triglide (Sciele Pharma
Inc.) [19].
The aim of this study was to evaluate the in vitro release of var-
ious formulations, representing the three different solubility
enhancing strategies selected and to link these observations to
their structural and physicochemical characteristics. Six intramus-
cularly (IM) injectable sustained release formulations for HIV pro-
phylaxis with a poorly soluble PI were developed and
physicochemically characterized. These six formulations (F1–F6,
listed in Table 1) represent the three different solubility enhancing
strategies selected. Samples F1–F3 are indicative of the first strat-
egy, being solid dispersions of the PI in a PLGA/PVP-based matrix. A
comparison of F1 and F2 demonstrates the influence of an increase
in the amount of PLGA (from 25 to 45 wt%). Additionally, F3 was
developed to assess the influence of the molecular weight of PVP
used. Samples F4 and F5 represent the second formulation strategy
which is the solid dispersion of the PI in a pure PLGA matrix. Here,Table 1
Overview of formulation composition and manufacturing method.
Formulation Composition (wt%) Manufacturing
method
Formulation 1 (F1) API/PLGA/PVP K30 30/25/45 Spray drying
Formulation 2 (F2) API/PLGA/PVP K30 30/45/25 Spray drying
Formulation 3 (F3) API/PLGA/PVP K12 30/45/25 Spray drying
Formulation 4 (F4) API/PLGA 30/70 Spray drying
Formulation 5 (F5) API/PLGA 30/70 Emulsion method
Formulation 6 (F6) API microsuspension Media millingthe influence of the manufacturing method was assessed by com-
paring a spray-dried formulation (F4) to a formulation prepared by
the emulsion method (F5). F6 is representative of the third formu-
lation strategy investigated, specifically particle size reduction.
A variety of complementary techniques were used to character-
ize these formulations physicochemically. The phase behavior of
the model formulations was studied by means of modulated differ-
ential scanning calorimetry (MDSC). The physical state of the drug
in the different formulations was examined by X-ray powder dif-
fraction. Chemical surface composition of the different micro-
spheres was analyzed by time-of-flight secondary ion mass
spectrometry (ToF-SIMS). Particle size was studied via laser diffrac-
tion. Subsequently the in vitro release behavior of the formulations
was tested in a surfactant containing phosphate buffer at pH 7.
As the six formulations differed in composition and manufac-
turing method, understanding how these parameters influence
the physicochemical characteristics and subsequent in vitro release
performance would allow rational selection of a formulation strat-
egy to obtain the desired in vitro release profile. Understanding and
control of the in vitro release behavior of a formulation is a first
step toward rationalized selection of a formulation strategy with
a desired release profile in vivo.2. Experimental section
2.1. Materials
Poly(lactic-co-glycolic acid) (PLGA) (lactide:glycolide molar
ratio of 75:25, inherent viscosity of 0.2 dL/g) was purchased from
PURAC Biomaterials (Gorinchem, the Netherlands). Polyvinylpyr-
rolidone K30 (PVP K30) (MW 44–54 kDa) and polyvinylpyrrolidone
K12 PF (PVP K12) (MW 2–3 kDa) were kindly donated by BASF
(Ludwigshafen, Germany). The API was a poorly soluble HIV prote-
ase inhibitor (PI) provided by Janssen (Beerse, Belgium). Disodium
hydrogenphosphate dodecahydrate (Na2HPO412H2O) and formic
acid were provided by Chemlab (Zedelgem, Belgium). Sodium
hydrogenphosphate monohydrate (NaH2PO4H2O) was supplied
by Merck (Darmstadt, Germany). Acros Organics (Geel, Belgium)
supplied dimethylformamide (DMF) and ammonium formate.
Polysorbate 80 (Tween 80) was obtained from Alfa Aesar GmbH
(Karlsruhe, Germany). Polyethyleneglycol 400 (PEG) was pur-
chased from Fagron (Waregem, Belgium). Polyvinyl alcohol (PVA)
(80% hydrolyzed, MW 9–10 kDa) was obtained from Sigma–Aldrich
(Diegem, Belgium). Tocopheryl polyethylene glycol 1000 succinate
(TPGS) was supplied by Eastman Chemical Company (Anglesey,
UK). Dichloromethane (DCM) and acetonitrile (ACN) were provided
by Fisher Scientific (Leicestershire, United Kingdom). All solvents
used were of HPLC or analytical grade. Ultrapure water was pro-
duced with an Elga Maxima system (Elga Ltd. High Wycombe
Bucks, United Kingdom).
2.2. Methods
Table 1 provides an overview of the composition and manufac-
turing method of various formulations tested. From here the for-
mulations will be indicated by their code F1–F6 as shown in
Table 1.
2.2.1. Formulation manufacturing
2.2.1.1. Spray drying. F1–F4 were spray dried with a Micro Spray
lab scale spray dryer (ProCepT, Zelzate, Belgium) starting from a
5% feed solution in DCM. The inlet temperature was set to 115 C
and the feed rate was 6 mL/min. The co-current drying air had a
flow rate of 0.2 m3/min and the atomizing air was supplied with
a pressure of 1.25 bar.
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were produced using an oil-in-water (o/w) emulsion method
(F5). 900.0 mg of API was dissolved in 30.0 mL DCM together with
2100.0 mg PLGA. This solution was emulsified in 150.0 mL of a
1.25% PVA solution for 5 min using an Ultra Turrax homogenizer
(IKA, Staufen, Germany) at 20,000 rpm to form the o/w emulsion.
During homogenization the sample was placed in an ice bath to
minimize heating. After the addition of 150.0 mL of distilled water,
the suspension was stirred overnight with a magnetic stirrer to
allow the organic solvent to evaporate as the microparticles hard-
ened. The resulting microparticles were harvested and washed
three times with deionized water. As a final step the microparticles
were freeze dried and consequently stored in a desiccator at room
temperature.
2.2.1.3. Media milling of the microsuspension. The API microsuspen-
sion (F6) was prepared using a roller mill (Peira, Turnhout,
Belgium) and glass vials of the appropriate size filled with zirco-
nium oxide grinding beads with a diameter of 1.0 mm (Tosoh
Corporation, Tokyo, Japan). All samples were ground for 24 h.
Subsequently these beads were replaced by beads of £ 0.5 mm.
After 48 h £ 0.3 mm beads were used for the next 16 days.
Suspensions consisted of 10% of drug in phosphate buffer of pH 7
containing 3.75% of TPGS.
2.2.2. Modulated differential scanning calorimetry
The bulk phase behavior of the spray-dried microspheres was
determined by MDSC (Q2000, TA Instruments, Leatherhead, UK).
Thermal Analysis Software (Version 4.4A) was used to analyze
the obtained data. Crimped aluminum pans (TA Instruments,
Brussels, Belgium) were selected for the analysis of the samples.
An empty pan was used as a reference and the masses of the refer-
ence pan and of the sample pans were taken into account. The DSC
cell was purged with a nitrogen flow rate of 50 mL/min.
Indium and n-octadecane were used for temperature calibra-
tion. The enthalpic response was calibrated with indium. The mod-
ulation parameters used were: a heating rate of 1 C/min, a period
of 40 s and an amplitude of 1 C. Calibration of the heat capacity
was done using sapphire. Formulations F1 and F2 were analyzed
from 20 C to 220 C whereas formulations F3–F5 were analyzed
from 20 C to 150 C. Glass transitions were analyzed in the
reversing heat flow signals.
2.2.3. Time-of-flight secondary ion mass spectrometry
Spray-dried samples were adhered to double-sided adhesive
tape in order to produce an immobile surface suitable for ToF-SIMS
analysis. The data were acquired using a ToF-SIMS IV instrument
(ION-TOF GmbH) equipped with a bismuth liquid metal ion gun
and a single-stage reflectron analyzer. Typical operating conditions
utilized a 25 kV Bi3+ primary ion source with a pulsed target current
of approximately 0.3 pA. A flood gun producing low energy elec-
trons (20 eV) was used to compensate for surface charging caused
by the positively charged primary ion beam on the insulating sam-
ple surface. A 4 mm  4 mm area of each sample was raster
scanned at a resolution of 100 pixels per mm. PLGA and PVP were
identified using C6H7O4 (m/z = 143), and C5H8O (m/z = 84) respec-
tively. The API was characterized by C8H7SO3 (m/z = 183). Prior to
sample analysis, reference materials were analyzed and the char-
acteristic ion peaks C6H7O4, C5H8O and C8H7SO3 were selected
and only present in PLGA, PVP and API respectively. Negative
polarity ToF-SIMS spectra showing the markers for API, PLGA and
PVP are shown in Fig. 1 of the Supplementary Information. Static
conditions were ensured by keeping the total primary ion beam
dose for every analyzed area below 1  1012 ions/cm2 throughout
the analysis. Data in the negative secondary ion polarities were col-
lected and analyzed using SurfaceLab 6 software (IONTOF). Thedata were acquired using the ‘‘high current bunched’’ setting on
the instrument to achieve high mass resolution. For any given sam-
ple, the measured secondary ion intensity for each ion peak
assigned to a specific material was normalized to the total inten-
sity count to enable a semi-quantitative comparison of the differ-
ent samples.
2.2.4. Particle sizing by laser diffraction
The particle size of the starting API and formulations F1–F5 was
determined by laser diffraction using a Sympatec RODOS instru-
ment (Sympatec, Clausthal–Zellerfeld, Germany). The measure-
ments were performed on samples dispersed in air. The particle
size of the microsuspension F6 was determined by laser diffraction
using a Malvern Mastersizer Micro Plus (Malvern Instruments Ltd.,
Worcestershire, UK). The measurements were performed on the
diluted microsuspension. The reported values are the 50% volume
percentiles (d(v,50)) calculated from volume distribution using
the Fraunhofer model.
2.2.5. X-ray powder diffraction
X-ray powder diffraction was performed at room temperature
with an X’Pert Pro diffractometer PW 3040/60 (PANalytical, the
Netherlands) and an X’Cellerator PX3015/20 (PANalytical, the
Netherlands) detector. The X’Pert Data Collector version 2.2c
(PANalytical, the Netherlands) was used for data collection and
the diffractograms were analyzed using the X’Pert Data Viewer
version 1.2a (PANalytical, the Netherlands). Samples were mea-
sured in reflection mode at room temperature by scanning from
4 to 30 2theta with a 0.017 step size every 200 s using a Cu-tube
(Ka k 1.5418 Å) set at 45 kV and 40 mA. Crystallinity of the sample
was calculated by dividing the AUC of the observed Bragg peaks by
the total AUC (i.e. AUCBragg peaks + AUChalo).
2.2.6. Determination of surface to mass ratio via nitrogen
physisorption
Nitrogen physisorption isotherms were recorded using a
Micromeritics TriStar II (Micromeritics, Norcross, Georgia). The
measurements were performed at 196 C. Samples were pre-
treated at 25 C for 2 h under nitrogen flow prior to analysis. The
total surface area was calculated using the Brunauer–Emmett–
Teller (BET) model.
2.2.7. In vitro drug release
Release experiments were performed at room temperature in
rotating test tubes (17 rpm) containing an amount of the pow-
ders corresponding to an API dose of 0.6 mg in 40.0 ml release
medium. In this way sink conditions were assured throughout
the experiment. The dissolution medium consisted of phosphate
buffer at pH 7 containing 0.25% Tween 80 and 2.5% PEG 400.
Samples were collected at 5, 15, 30, 60, 240, 480 and 1440 min,
filtered over a Chromafil RC-20/15 cellulose acetate filter with a
pore size of 0.2 lm (Macherey–Nagel, Düren, Germany) and sub-
sequently analyzed by high performance liquid chromatography
(HPLC) with UV detection. Experiments were performed in
triplicate.
2.2.8. High performance liquid chromatography (HPLC) assay
A Waters HPLC system (Milford, USA) consisting of a Waters
1525 Binary HPLC pump, a Waters 717plus Autosampler, set at a
10 lL injection volume, and a Waters 2487 Dual Lambda
Absorbance detector, set at a detection wavelength of 255 nm,
were used to quantify drug release. A Waters Sunfire C18 3.5 lm
(100 mm  4.6 mm) column was utilized. Samples were injected
in duplicate and analyzed using a 1.0 mL/min flow rate at room
temperature. The average result of both injections was reported.
The mobile phase consisted of a 50 mM formate buffer (pH 4)
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330i pH meter (Weinheim, Germany). The buffer was filtered over
a 0.45 lm polytetrafluoroethylene (PTFE) membrane and the
mobile phase was degassed prior to use. Standard curves were
made in dimethylformamide (DMF) and were linear over the con-
centration range used (1.56–100 lM). Data were analyzed using
Breeze software Version 3.30 (Waters).2.2.9. Statistical analysis
Statistical differences between the observed in vitro release
were evaluated for all formulations at each time point via one-
way ANOVA. A Bonferroni post hoc test was performed at an a level
of 0.05 (GraphPad Prism 5 for Windows; GraphPad Software Inc.,
San Diego, USA).Fig. 1. MDSC of selected formulations. From top to bottom reversing heat flow for
formulations F1–F5. The arrows indicate the glass transitions.3. Results
3.1. Physicochemical characterization
Particle size was determined by laser diffraction and the d50
value for the various formulations was compared (Table 2). The
d(v,50) value of F5, 5.62 lm, was larger than that of the other for-
mulations (2.99 lm on average). A 14-fold reduction in particle
size was achieved by milling the pure API to obtain F6.
Nitrogen physisorption tests allowed an estimation of the total
surface area per mass for F1–F5 where F5 had an average of 2.6-
fold higher surface area compared to the other formulations tested
(Table 2).
MDSC was used to thermally characterize the phase behavior of
the model formulations F1–F5 as well as the physical state of the
API in these formulations. The spray-dried pure compounds were
identified by their glass transition temperature (Tg) being about
38 C for PLGA, 56 C for the API and 174 C for PVP under the given
experimental conditions. The phase behavior of the various sam-
ples was studied through their Tgs, which were observed in the
reversing heat flow curves (Fig. 1). F1–F3 demonstrated two mix-
ing Tgs, the first one approximating to the Tg of PLGA and the sec-
ond one being a broad and weak Tg shifting toward the Tg of pure
PVP. For F1 and F2 the Tg of the API (around 56 C) was not
observed. However, for F3 an additional Tg was observed around
55 C. For the binary formulations, F4 and F5, one mixing Tg was
observed in the temperature region of the Tg of PLGA. Additionally,
for F5 a melting endotherm was observed with an onset melting
temperature of 111 C.
The physical state of the drug in F5 and F6 was examined by
XRPD. For both formulations Bragg peaks were observed. The total
crystallinity of the sample was estimated to be 17% for F5 and 29%
for F6.
The API surface coverage of F1–F5 was analyzed by ToF-SIMS.
The spatial distribution of the API and PLGA at the sample surface
of F1–F5 is presented in the secondary ion maps shown in Fig. 2. A
negligible amount of PVP is detected at the particle surface corre-Table 2
50% Volume percentiles (d(v,50)) obtained by laser diffraction and total surface area
determined by nitrogen physisorption.
Sample d (v,50) (lm) Surface area (m2/g)
API 37.7 –
F1 2.99 2.4
F2 2.98 3.8
F3 3.02 1.3
F4 3.23 1.6
F5 5.62 6.0
F6 2.73 –sponding with previous studies. At the spatial resolution of the
ToF-SIMS data acquired, the drug appears to be homogeneously
distributed at the surface of the model formulations, illustrated
by the absence of separate regions of API. Separate regions of API
would be denoted as separate bright red spots in the negative
polarity overlay images.
Fig. 3 shows the C8H7SO3 ion intensity which is indicative of the
API at the sample surface and hence depicts a relative measure of
API surface coverage for the various formulations. It is clear that F5
has a higher presence of API at the microsphere surface.3.2. In vitro release
In vitro release of the formulations was tested up to 24 h in a
surfactant containing phosphate buffer at pH 7 as release medium
(Fig. 4). The addition of surfactant to the release medium allowed
accelerated release testing of these formulations, originally devel-
oped for long-term release. Differences in release were observed
between the various model formulations.
Release of F1 during the entire course of the experiment
(5–1440 min) was comparable to F5 and higher than F2 and F3
which both showed similar release behavior with approximately
60% drug release after 24 h. F6 had a significantly higher drug
release in contrast to F4 which released a significantly lower
amount of drug compared to all other formulations. The microsus-
pension (F6) gave an immediate and complete drug release, in con-
trast to F4 which had a maximum release of 5% of drug after 24 h.
Regardless of their identical composition F5 showed a remarkably
higher release compared to F4 with a maximum cumulative release
close to 80%. Significant differences in burst release were observed
for the polymeric formulations F1–F5. For F4 no burst was
detected, whereas for F2 and F3 a comparable burst approximating
10% and for F1 and F5 a burst close to 20% was observed.4. Discussion
The influence of composition and manufacturing method upon
the physicochemical properties of the model formulations F1–F6
representing three different formulation strategies was assessed.
These findings were used to explain observed differences and sim-
ilarities between the in vitro release profiles of the different
formulations.
Fig. 2. ToF-SIMS intensity maps for formulations F1–F5. Panel a shows results of the total intensity signal. Panels b and c show negative polarity images of API (m/z = 183) and
PLGA respectively (m/z = 143). Panel d shows the negative polarity overlay images (API in red, PLGA in green) (1 mm  1 mm scan size, n = 4). (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
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The size of the particles of formulations F1–F6 was assessed by
laser diffraction. Particles of F5 had a larger d(v,50) value (5.62 lm)
compared to the other formulations (2.99 lm on average) as wellas an average 2.6-fold higher surface area (Table 2). The different
manufacturing method of F5 compared to F1–F4 (emulsion
method and spray drying respectively) is thought to be responsible
for these observed differences in particle characteristics. As surface
area increases with decreasing particle size, assuming comparable
Fig. 3. Histogram representing the intensity atm/z = 183 (C8H7SO3, marker API) for
formulations F1–F5 (1 mm  1 mm scan size, n = 4).
Fig. 4. Cumulative in vitro release of formulations F1–F6. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of
this article.)
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face to mass ratio indicates an additional origin of surface area,
namely porosity. Hence particles of F5 are more porous compared
to the microspheres representing F1–F4. This porosity originates
from its manufacturing process, where the evaporation of organic
solvent homogenized in a water phase results in pores in the pre-
cipitating particles.
MDSC was used to thermally study the phase behavior of F1–F5.
Preceding work has already shown that spray drying a formulation
composed of API/PLGA/PVP 30/25/45 wt% results in hollow spheres
with a PLGA rich surface layer (containing small amounts of PVP),Fig. 5. Schematic representation of the microspheres composing the polymeric formula
references to color in this figure legend, the reader is referred to the web version of thian underlying PVP-rich layer (containing small amounts of PLGA)
and a molecular dispersion of the API in these polymeric layers.
The present study confirms these findings for F1 and F2 by the
observation of two mixing Tgs, the first one approximating to the
Tg of PLGA and the second one shifting toward the Tg of pure PVP
(Fig. 1). The absence of a Tg around 56 C (Tg of the API) indicates
that the API is molecularly dispersed in a phase separated system
made up of a PLGA-rich phase and a PVP-rich phase. In addition
F3 displays a third Tg at 55 C which is close to the Tg of the pure
drug. This is an indication of the presence of a third amorphous
phase mainly consisting of API.
The mixing Tg observed in F4 and F5 suggests a glass solution of
API in the PLGA matrix. Additionally for F5 a phase separated crys-
talline API fraction is present. Based on XRPD analysis this fraction
was estimated to be 17% of the total formulation, while the micro-
suspension was estimated to contain 29% of crystalline drug
content.
ToF-SIMS was used to study the surface chemistry of the micro-
particles. The results indicated that F5 contained a relatively higher
amount of API at the microsphere surface compared to the poly-
meric formulations (Figs. 2 and 3). The different manufacturing
method of F5 compared to F1–F4 (emulsion method and spray dry-
ing respectively) is believed to be responsible for the observed dif-
ference in API surface coverage. This difference in manufacturing
method results in different droplet generation, evaporation kinet-
ics and therefore solid disposition and particle formation.
The physicochemical characterization of these model formula-
tions showed that all ternary formulations (F1–F3) were made up
of a PLGA-rich surface layer containing small amounts of PVP
and an underlying PVP-rich phase containing small amounts of
PLGA. The API was molecularly dispersed in the polymeric matrix.
Additionally for F3, a separate amorphous drug phase was
detected. The binary formulations F4 and F5 contained a molecular
dispersion of the drug as well. Furthermore, F5 exhibited a crystal-
line drug fraction and a higher drug surface coverage. The micro-
suspension, F6, comprised of both crystalline and amorphous API.
The six formulations differed in composition and manufacturing
method and consequently in structural and physicochemical char-
acteristics. The results of this physicochemical and structural char-
acterization are schematically summarized in Fig. 5.4.2. In vitro release
4.2.1. Strategy 1: solid dispersions in a biphasic matrix consisting of
water-insoluble PLGA and water-soluble PVP (F1–F3)
Previous work demonstrated that for the ternary systems (API/
PLGA/PVP) the release mechanism is dominated by fast dissolution
of the small domains of PVP present in the PLGA layer due to the
high solubility of PVP. The resulting pores in the PLGA surface layer
allow ingression of aqueous fluids into the particles, followed by
fast dissolution of the molecularly dispersed API and diffusion
out of the microspheres.
The results for F1 and F4 allow a comparison of a PLGA/PVP-
based matrix to a PLGA-based matrix respectively. Hence thetions F1–F5. PLGA in green, PVP in red and API in yellow. (For interpretation of the
s article.)
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F1 resulted in a higher amount of drug released compared to F4
(Fig. 4). This can be accredited to the fact that for F1 the resulting
pores (originating from dissolved PVP) allow water ingression dee-
per into the particle compared to eroding a bulk PLGA matrix (F4).
For F1 an increased surface area is exposed to the release medium
with an increase in drug dissolution and drug release as a result.
Altogether this indicated that the inclusion of PVP in the PLGA
matrix is beneficial for the total amount of drug released. In con-
trast to the microsuspension, F6, PLGA/PVP-based matrices did
not result in an immediate drug release and therefore would be
more suitable for sustained release applications.
Previous research evinced that the thickness of the PLGA sur-
face layer increased with an increase in the amount of PLGA in
the microspheres [5]. The influence of the thickness of the PLGA
surface layer was examined by comparing F1 with F2 where the
weight percentage of PLGA in the formulation was raised from
25 wt% to 45 wt%. The in vitro release results suggested that an
increased thickness of this PLGA surface layer had a prolonging
influence upon drug release via a decrease in release rate (Fig. 4).
As PLGA is water-insoluble it is expected that the thickness of this
PLGA surface layer has an influence upon drug release kinetics
where the thicker the PLGA layer the more prolonged the observed
release. This suggests that for the PLGA/PVP-based formulations
the release rate can be tailored by the amount of PLGA present.
Additionally, the influence of the molecular weight of PVP was
probed. The results indicated that there was no influence of using
PVP K30 (MW 44–54 kDa) compared to PVP K12 (MW 2–3 kDa) on
the in vitro release profiles (Fig. 4). This is most likely due to the
instantaneous dissolution of both PVP types when brought into
contact with water. It is possible that the selection of PVP with
higher molecular weight (e.g. PVP K90) might slow down release
considering its slower dissolution and higher viscosity of the
resulting solution. However, this higher molecular weight com-
pound requires thorough revision and optimization of the spray
drying process because of the higher viscosity of the feed solution.
Observed differences in burst release between the PLGA/PVP-
based formulations can most likely be attributed to differences in
the structure and hence PVP pore network of these formulations.
4.2.2. Strategy 2: solid dispersions in a water-insoluble PLGA matrix
(F4–F5)
The significantly slower release of F4 (Fig. 4) is not surprising, as
these types of PLGA-based matrices are already well established as
controlled release formulations with some commercial examples
such as Trelstar Depot (Debio RP) [14], and RisperdalConsta
(Janssen) [15]. However, the restricted amount of drug released
(5% after 24 h) might be a limitation of this formulation approach
compared to the other strategies tested.
Notwithstanding its identical composition compared to F4, F5
demonstrated some physicochemical and structural differences
which are presumed to influence the observed release. The higher
drug surface coverage of F5 combined with its crystalline drug
fraction (17%) is expected to result in a lower drug solubility com-
pared to when the drug is present as a homogeneously distributed
glass solution. Nevertheless, F5 resulted in a significantly higher
burst and overall drug release compared to F4 (Fig. 4). This can
be explained by the observed porosity of this formulation as indi-
cated by its increased surface to mass ratio. The pores would allow
ingression of water into the PLGA matrix. Owing to the surfactant
present in the release medium water could quickly penetrate, even
in this initially hydrophobic matrix. Formulation F5 demonstrates
a release profile comparable to F1 which can be understood by
the fact that the pores initially present in F5 exhibit the same func-
tion as pores originating from rapidly dissolving PVP in the ternary
formulations F1–F3. Based upon these findings the porosity of thePLGA matrix is the determining factor for adequate drug release
from this matrix. The origin of the porosity (the manufacturing
method (F5) or the fast dissolution of PVP (F1)) does not seem to
have influence upon the observed in vitro performance of the for-
mulations. However, it is likely that in vivo the amount of drug
released from PLGA/PVP-based formulations will be favorable
compared to PLGA-based formulations. The reason for this is the
hydrophilic nature of PVP which will favor water ingression into
the pore network. In vitro the presence of surfactant in the release
medium might lead to a disproportional advantage of a porous
PLGA-based formulation compared to the in vivo situation.4.2.3. Strategy 3: particle size reduction (F6)
Particle size reduction is a well-known strategy to increase drug
dissolution rate of a drug via an increase in surface area [13,16,17].
However, for poorly soluble APIs particle size reduction will still
result in a relatively low dissolution rate and hence sustained
release [1,20,21]. Consequently, for this type of API, particle size
reduction is often used as a strategy to develop a sustained release
formulation [20] which was the approach investigated here by
means of F6.
However, the observed release profile illustrates that of all the
formulations tested, this microsuspension is the least suitable for
long term release applications of this API as particle size reduction
did not result in a slow dissolution rate for this formulation (Fig. 4).
The immediate and complete drug dissolution of the microsuspen-
sion (F6) observed in vitro can be attributed to the reduction in par-
ticle size. Therefore, for this drug, particle size reduction was a
suitable strategy to increase dissolution rate but it appears to be
less applicable for the development of a sustained release
formulation.
For the various formulation strategies both a porous PLGA-
based formulation (F5) and PLGA/PVP-based formulations
(F1–F3) resulted in vitro in sustained release of the poorly soluble
API with over 50% of drug released after 24 h.5. Conclusions
Physicochemical characterization and in vitro evaluation of var-
ious formulation strategies for controlled release injectables of a
poorly soluble HIV protease inhibitor were performed. A formula-
tion strategy based on the molecular dispersion of a poorly soluble
drug into a biphasic PLGA/PVP matrix was evaluated. This strategy
was compared to other solubility enhancing approaches, namely
solid dispersions in a pure PLGA matrix and particle size reduction.
Six model formulations were tested, representing these three for-
mulation approaches.
Depending on composition and manufacturing method, the
model formulations varied in particle size, porosity, phase behav-
ior, surface coverage and physical state of the API. These findings
gave insight in the in vitro release behavior and resulted in an
understanding of the observed differences and similarities in
release of the various formulations. For PLGA-based formulations
porosity was identified as a critical parameter influencing in vitro
drug release, whereas the release rate of PLGA/PVP-based formula-
tions could be tailored by changing the thickness of the PLGA sur-
face layer. For the API studied, particle size reduction was a
suitable strategy to increase dissolution rate but it was less appli-
cable for the development of a sustained release formulation as it
resulted in an immediate and complete in vitro drug release.Conflict of interest
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